UNSPSC 51112031: Ribociclib

Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6.

UNSPSC 51112031 Ribociclib, a Commodity code, sees no recent state and local procurement activity. The code records no substantive solicitations for ribociclib—a CDK 4/6 inhibitor pharmaceutical—in the dataset of state and local contract opportunities posted since January 2026. The single nominally tagged record (Seminole County's naloxone and drug deactivation systems procurement, IFB 60459723LAS) concerns emergency medical supply distribution and falls outside the pharmaceutical manufacturing and wholesale distribution scope that ribociclib occupies. State and local health departments, correctional authorities, Medicaid programs, and institutional healthcare buyers occasionally source specialty oncology pharmaceuticals through group purchasing organizations (GPOs), state pharmaceutical contracts, and cooperative purchasing vehicles, but direct state and local RFPs for branded or generic pharmaceutical drugs at the UNSPSC 511 Commodity tier are rare; most procurement flows through pharmacy benefits programs, prime pharmaceutical wholesalers under standing agreements, or federal 340B programs rather than open solicitation.

The absence of recent activity under this code does not signal zero opportunity—ribociclib and similar specialty pharmaceuticals move through state Medicaid contracts, state employee health plans, county hospital systems, and correctional health procurement—but acquisition occurs primarily through GPO contracts (such as MMCAP, HealthTrust, Premier, Vizient), state health department framework agreements, or pharmaceutical wholesale master agreements rather than competitive bid cycles visible in public notice databases. A firm pursuing this market should monitor state pharmacy benefit manager RFPs, county health system drug formulary contracts, Medicaid agency pharmaceutical purchase agreements, and GPO solicitations rather than direct state and local postings under this commodity code.